Is DHT production by 5a-reductase friend or foe in prostate cancer?

Takeo Kosaka, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The first advance in the history of studies on prostate cancer (PCa) and androgens was the development of treatment with castration and administration of estrogen by Charles B. Huggins, who won the Nobel Prize in Physiology and Medicine. Since then, and for 70 years, androgen deprivation therapy has been the standard therapy for advanced PCa and the center of studies on PCa. However, recent advances have shed light on the relationship between androgens and the development or the progression of PCa. The use of 5AR inhibitors to prevent progression of PCa continues to be widely discussed. Discussion has been fueled by the findings of two large randomized, placebo-controlled trials: the Prostate Cancer Prevention Trial with finasteride and the Reduction by Dutasteride of Prostate Cancer Events trial. Does the development of PCa or progression to castration-resistant PCa depend on dihydrotestosterone (DHT)? Here, we summarize and discuss recent topics of local androgen production of DHT in PCa.

Original languageEnglish
Article number247
JournalFrontiers in Oncology
Volume4
Issue numberSEP
DOIs
Publication statusPublished - 2014

    Fingerprint

Keywords

  • 5α-reductase inhibitors
  • Androgen receptor
  • C4-2AT6
  • Prostate cancer
  • Steroidogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this